Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02136862 · ClinicalTrials.gov registry record
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 165
- Enrollment target
NCT02136862: Completed study, sponsored by Genzyme, a Sanofi Company.
NCT02136862 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 165 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02136862 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 165 participants
- Enrollment target
Study Summary
There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients. Patients with a confirmed diagnosis of Alport syndrome who have qualifying GFR will be considered for enrollment. The sequential sampling of subjects' urine and/or blood will allow an assessment of the rate of change of established clinical endpoints, such as GFR and/or the rate of change of other renal biomarkers (proteinuria and β-2 microglobulin) in subjects whose renal function is steadily declining. The identification of surrogate markers that track the decline of renal function and could correlate with time to end-stage renal disease (ESRD) is a key goal of the natural history study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2017-12-18 |
What the finished NCT02136862 record still lists
NCT02136862 is an observational study that tracks outcomes without assigning an intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02136862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02136862 about?
NCT02136862 is a clinical study titled "ATHENA: Natural History of Disease Study in Alport Syndrome Patients". There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients. Patients with a confirmed diagnosis of Alport syndrome who have qualifying G...
What is the current status of trial NCT02136862?
This trial is currently completed. The enrollment target is 165 participants. The study started on 2014-09-04. Estimated completion is 2017-12-18.
Who is sponsoring clinical trial NCT02136862?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI